Lupin Ltd

{"amount":12}

{"actualRevenue":74746600000,"estimateRevenue":71087000000,"revenueSurprise":3659600000,"revenueSurprisePercent":5.148058013420175,"actualEPS":34.75,"estimateEPS":27.42066,"surprise":7.329339999999998,"surprisePercent":26.72926180478514}

{"actualRevenue":71675200000,"estimateRevenue":69371000000,"revenueSurprise":2304200000,"revenueSurprisePercent":3.321560882789639,"actualEPS":34.99,"estimateEPS":28.6386968,"surprise":6.351303200000004,"surprisePercent":22.17734712006869}

{"actualRevenue":70475100000,"estimateRevenue":67599000000,"revenueSurprise":2876100000,"revenueSurprisePercent":4.254648737407358,"actualEPS":32.28,"estimateEPS":25.5785771,"surprise":6.701422899999997,"surprisePercent":26.19935766481708}

{"actualRevenue":62683400000,"estimateRevenue":66208000000,"revenueSurprise":-3524600000,"revenueSurprisePercent":-5.323525857902369,"actualEPS":26.62,"estimateEPS":23.262138,"surprise":3.357862000000001,"surprisePercent":14.43488126499809}

{"description":"Lupin won USFDA approval for famotidine injection USP, 20 mg/2 mL, for ulcers and GERD; it will be made at Nagpur. The article also cites strong Q4FY26 and FY26 profit and revenue growth.","url":"https://www.cnbctv18.com/market/stocks/lupin-share-price-gets-us-fda-nod-for-famotidine-injection-ulcers-gerd-treatment-ws-l-19905136.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Lupin Ltd’s Q4 2026 earnings call highlighted record revenue and profit growth, while management warned of rising competition and outlined strategic expansion plans.","url":"https://finance.yahoo.com/sectors/healthcare/articles/lupin-ltd-bom-500257-q4-070153235.html","sentiment":"Positive","domain":"Yahoo Finance"}

{"description":"Lupin said its US business should stay above $1 billion in FY27, with biosimilars, injectables and specialty products driving growth; it also guided for full-year margins near 25%.","url":"https://www.cnbctv18.com/market/earnings/lupin-q4-results-us-business-to-stay-above-1-billion-biosimilars-specialty-portfolio-to-drive-growth-19901847.htm","sentiment":"Positive","domain":"CNBCTV18"}

{"description":"Lupin shares fell despite reporting a 90% jump in Q4 profit and announcing its highest-ever dividend, highlighting a strong earnings beat and shareholder return.","url":"https://www.msn.com/en-in/money/markets/lupin-shares-slump-despite-90-jump-in-q4-profit-highest-ever-dividend-announcement/ar-AA22Fgdb?ocid=BingNewsVerp","sentiment":"Positive","domain":"NDTV Profit on MSN"}

{"description":"Lupin reported Q4 net profit up 88% to ₹1,468.67 crore and revenue up 32% to ₹7,474.66 crore, with record US sales of $371 million and a ₹18 per share dividend proposal.","url":"https://www.cnbctv18.com/market/lupin-share-price-q4-result-reaction-record-us-sales-margin-expansion-india-row-52-week-high-ws-l-19901543.htm","sentiment":"Positive","domain":"CNBCTV18"}